Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes.
about
Interventions for latent autoimmune diabetes (LADA) in adultsInterventions for latent autoimmune diabetes (LADA) in adultsLost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitusRandomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adultsInsulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes.Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.Latent autoimmune diabetes of adulthood. Unique features that distinguish it from types 1 and 2.Immunomodulation for the prevention of SPIDDM and LADA.Effect of pioglitazone on the course of new-onset type 1 diabetes mellitusManagement of patients with type 1 diabetes in the hospital.Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-obese Diabetic MiceElevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes.IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?The peroxisomal proliferator-activated receptor gamma isoform 2 (PPARgamma2) is an established susceptibility marker for type 2 diabetes (T2D).[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes.
P2860
Q24234365-07898288-921E-4BCE-9E59-CEA52FDF17EAQ24244270-F1F99628-3691-458C-94A8-798F44BED013Q26864403-30AAD96C-640E-447A-A53C-F8FDFE607681Q33354779-21B05693-0B85-4B72-B462-DF96922159C4Q35612704-D8B3350A-5BB6-410E-A8C1-1FDDE4547E0CQ36068458-95796199-91F7-4C27-B33D-10AB88007869Q36077018-4BCF36B0-EF6B-4F65-9EC8-A3CB154C079EQ36666070-58A87A8E-E9E3-49C2-90FF-97AAFD0FE5B4Q37472536-A58BDF98-BCF6-48CC-86E3-B715AEE704D7Q38176514-271621D9-F4D6-4589-92C4-58EEDC55054CQ38747073-ADBB55B7-4211-40E0-80C0-7B4A46994930Q39626208-DFB38237-A244-4DF6-8EF6-75ACD9CB42EFQ42676214-4063FF03-5223-42B5-9D32-53B779170644Q46520187-71B11C14-BCF7-4618-8EDC-23187B2315DAQ46625434-914828C9-882E-4318-9D69-D65BDC1026E3Q51775383-3712E4D0-9A9F-42EF-B2B4-15B3CD5C7F52
P2860
Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Thiazolidinediones for the pre ...... ons for human type 1 diabetes.
@en
Thiazolidinediones for the prevention of diabetes in the non-obese diabetic
@nl
type
label
Thiazolidinediones for the pre ...... ons for human type 1 diabetes.
@en
Thiazolidinediones for the prevention of diabetes in the non-obese diabetic
@nl
prefLabel
Thiazolidinediones for the pre ...... ons for human type 1 diabetes.
@en
Thiazolidinediones for the prevention of diabetes in the non-obese diabetic
@nl
P2860
P356
P1476
Thiazolidinediones for the pre ...... ons for human type 1 diabetes.
@en
P2093
Paolo Pozzilli
Philip E Beales
P2860
P304
P356
10.1002/DMRR.262
P577
2002-03-01T00:00:00Z